A Phase 4 interventional study of Liraglutide and metformin and Metformin in PCOS, Obesity and Infertility, sponsored by Peking University Third Hospital. Recruiting at 3 sites in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-05-29.
Sponsored by Peking University Third Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.
Among the 79 studies testing liraglutide in Obesity, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is one of 37 in phase 4, and was the 76th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Brigham and Women's Hospital · Sites in South Africa
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
Emirates Health Services (EHS) · Sites in United Arab Emirates
Ages 22–60 · Healthy volunteers
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–75
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 37
First in 2007; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 890 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 70 across the 79 interventional studies. Of the 54 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 79 have an industry lead sponsor. The 10 most frequent:
Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 275 are open to participants now.
Peking University Third Hospital has 6 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
2 of the studies testing liraglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT02944500Beth Israel Deaconess Medical CenterSaxenda: Underlying Mechanisms and Clinical Outcomes | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies testing liraglutide in Obesity, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. Previous studies have suggested that liraglutide improves glucose metabolism, body weight, and inflammation levels in obese women with PCOS, and improves sex hormone profiles and menstrual cycles, possibly contributing to increased fertility.
Therefore, this project intends to test the following hypothesis through a large sample randomized controlled trial in obese and infertile PCOS women who are assisted by in vitro fertilization-frozen embryo transfer (IVF-FET), using liraglutide before transplantation to reduce weight can improve the live birth rate of assisted reproduction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Liraglutide 3.0 mg or maximum tolerable dose/day and metformin 1500 mg/day
Drug: Liraglutide and metformin
Metformin 1500 mg/day
Drug: Metformin
Drug pages: LiraglutideStudies of LiraglutideLiraglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Liraglutide 3.0 mg or maximum tolerable dose/day × 12 weeks and metformin 1500 mg/day until pregnancy.
Metformin 1500 mg/day until pregnancy
Live birth rate associated with single cycle frozen embryo transfer
The rate of live birth of intervention and control groups
Time frame: At delivery
Clinical pregnancy rate of single cycle frozen embryo transfer
Viable intrauterine pregnancy confirmed by ultrasound
Time frame: Thirty days after the embryo transplantation
Incidence of newly diagnosed diabetes or gestational diabetes during pregnancy
Newly diagnosed diabetes or gestational diabetes at 28 weeks of pregnancy confirmed by 75 g oral glucose tolerance test。
Time frame: At 28 weeks of pregnancy
Pregnancy outcome and complications
Rate of miscarriage, multiple pregnancies, pregnancy induced hypertension, preeclampsia, HELLP syndrome, prematurity (\< 37 weeks), macrosomia (birth weight \> 4 kg), induction of labour, prolonged duration of labour, caesarean section, assisted delivery, peripartum increased blood loss (≥ 800 ml).
Time frame: From baseline to delivery
Birth weight for gestational age
Birth weight percentile for gestational age for neonatal sex
Time frame: At delivery
Apgar scores
Apgar scores (0\~10) of the newborns at delivery
Time frame: At delivery
Other perinatal outcomes
Rate of major birth defects, stillbirth, neonatal complications, and neonatal admission to a neonatal intensive care unit.
Time frame: At delivery
Accumulated live birth rate
Accumulated liver birth rate associated with the pregnancy achieved during the first 6 months of the study
Time frame: At delivery
Accumulated clinical pregnancy rate
Accumulated clinical pregnancy rate achieved during the first 6 months of the study
Time frame: At month 6
Weight
Measured by the same weight scale
Time frame: At baseline, and week 12
Oral glucose tolerance test
oral glucose tolerance test was conducted to test glucose metabolism
Time frame: At baseline, week 12, 28 weeks of pregnant, six weeks after delivery
HbA1c
Glycosylated hemoglobin
Time frame: At baseline and week12
Rate of insulin usage during pregancy
Time frame: Throughout pregnancy
Number of menstrual cycles
Time frame: From to 12 weeks
Free testosterone index
Free testosterone index
Time frame: At baseline, week 12
Drug-related adverse reactions
Drug-related adverse reactions, including but not limited to, nausea, diarrhea, vomiting, decreased appetite, dyspepsia, constipation, drug allergy, hypoglycemia, acute pancreatitis, acute gallbladder disease.
Time frame: During the treatment with liraglutide or metformin
Anxiety
Measured by Generalized Anxiety Disorder-7 scores, from 0 (no anxiety) to 21 (severe anxiety)
Time frame: Baseline and week 12
Depression
Measured by Patient Health Questionnaire-9 score from 0 (no depression) to 27 (severe depression)
Time frame: Baseline and week 12
Quality of life specifically for PCOS individuals
Measured by Modified Polycystic ovary syndrome Quality of life, with each item scores from 1 (maximum impairment) to 7 (no impairment)
Time frame: Baseline and week 12
Major congenital malformations
Identified in the Birth Defects Prevention and Control Plan (2023-2027) issued by the National Health Commission of the People's Republic of China
Time frame: Six weeks after live birth
Costs
The cost per live birth for the different intervention groups, considering both direct medical and non-medical costs, as well as indirect costs.
Time frame: At delivery
Plan to share: Undecided — De-identified individual participant data will be available if researchers provide a methodologically sound proposal and contact to the principal investigator. Data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.
Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 48 months is above that.
Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Liraglutide · Metformin
Peking University Third Hospital →